Voorburg, Netherlands
Voorburg, Netherlands

Time filter

Source Type

Mogarekar M.R.,Srtr Government Medical College | Kulkarni S.K.,Diagnostic Laboratory
Archives of Medical Research | Year: 2015

Background and Aims: Atherosclerosis, the root cause of cardiovascular disease (CVD), has a number of risk factors-some modifiable and some not. CVD increases in women particularly during the postmenopausal period. Small dense low-density lipoprotein (sdLDL), a subclass of LDL, is an important determinant of atherosclerosis in postmenopausal women. Paraoxonase1 (PON1) is a high-density lipoprotein (HDL)-associated enzyme that prevents oxidative modifications in LDL and HDL. With this background, we studied the sdLDL-C, PON1 and lipid profile in postmenopausal women to compare between quality and quantity of LDL. Methods: We studied 80 pre- and postmenopausal women (40/group). The following parameters were studied: lipid profile, sdLDL-C and PON1 levels. With proper statistical tools the correlation between these parameters was studied. Results: Postmenopausal women, in comparison with premenopausal women, have significantly increased levels of serum triglycerides and sdLDL-C and very-low-density lipoprotein cholesterol (VLDL-C) and significantly decreased levels of HDL-C and PON1. PON1 activity was negatively correlated with age, TC, TG, LDL-C and sdLDL-C (r = -0.574, -0.119, -0.226, -0.473 and -0.455, respectively) and positively correlated with HDL-C (r = 0.368), whereas sdLDL-C was positively correlated with age, TC, TG, LDL-C (r = 0.633, 0.485, 0.561 and 0.705, respectively) and negatively with HDL-C (r = -0.235). Stepwise multiple regression analysis demonstrated HDL-C and menopausal status as the best determinant for PON1 (R2 = 0.320, p < 0.05) and menopausal status, LDL-C, TG, and TC were the best determinants for sdLDL-C (R2 = 0.606, p < 0.05). Conclusion: The results of the present study suggest quality, i.e., sdLDL-C, is more important than only LDL-C levels. Similarly, decrease in PON1 and increase in sdLDL-C go hand in hand. This shows that antioxidant capacity is compromised with a qualitative downfall in lipoproteins in postmenopausal women. © 2015 IMSS.

News Article | November 17, 2016
Site: www.prnewswire.co.uk

According to a new market research report "Immunoassay Market by Product & Service (Reagents & Kits, Analyzers, Software, Services), Technique (ELISA, Rapid Test), Application (Infectious Diseases, Endocrinology, Oncology), End User (Clinical Labs, Hospitals) - Global Forecast to 2021" published by MarketsandMarkets, the global market is expected to reach USD 25.45 Billion by 2021 from USD 17.16 Billion in 2016, at a CAGR of 8.2% from 2016 to 2021. Browse 139 market data Tables and 44 Figures spread through 204 Pages and in-depth TOC on "Immunoassay Market" Early buyers will receive 10% customization on this report. This report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the Immunoassay Market along with the estimates and forecasts of the revenue and market share analysis. The major factors driving the growth of this market are raising incidences of chronic diseases, extensive use of immunoassays in oncology, technological advancements, and cost-effectiveness & rapid analysis of immunoassays. This report segments the Immunoassay Market on the basis of product & service, technology, application, end user, and region. Based on product & service, the Immunoassay Market is segmented into reagents & kits, analyzers, and software & services. The reagents & kits segment is further segmented into ELISA reagents, rapid test reagents, western blot reagents, ELISPOT reagents, RIA reagents, and PCR reagents. The analyzers segment is further categorized into purchase mode and type. By purchase mode, the analyzers segment is segmented into reagent rental purchase and outright purchase and by type; these are divided into open-end systems and closed-ended systems. In 2016, the reagents & kits segment is expected to dominate the global Immunoassay Market. Factors driving this segment include rising number of immunoassay tests due to the increase in aging population, rising prevalence of chronic and infectious diseases, and increased variety of reagents and analytical techniques. Based on technology, the Immunoassay Market is segmented into ELISA, rapid tests, western blot tests, ELISPOT, RIA, and PCR. ELISA is further segmented into platform and generation. On the basis of platform, the ELISA market is divided into chemiluminescence immunoassays (CLIA), fluorescence immunoassays (FIA), and colorimetric immunoassays (CI). On the basis of generation, the ELISA market is further divided into first generation, second generation, third generation, and fourth generation and above. The ELISA segment is expected to account for the largest share of the market, owing to expanding use of immunoassay tests in cancer, point-of-care in vitro diagnostics, infectious disease testing, and therapeutic drug level monitoring. On the basis of application, the Immunoassay Market is segmented into infectious diseases, endocrinology, bone and mineral disorders, oncology, cardiology, hematology and blood screening, autoimmune diseases, toxicology, neonatal screening, and other applications. The infectious diseases segment is expected to account the largest market share in 2016. On the basis of end user, the Immunoassay Market is segmented into hospitals, clinical laboratories, blood banks, research & academic laboratories, pharmaceutical companies, CROs, biotechnology companies, and other end users. The hospitals segment is expected to account for the largest share of the global Immunoassay Market in 2016. Major factors driving the growth of this market are the rising prevalence of chronic diseases and increasing healthcare infrastructure. On the basis of region, the Immunoassay Market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share of the market during the forecast period. Growth in this regional segment is driven by factors such as technological advancement in the immunoassay products and rising incidence of chronic diseases. Key players in the Immunoassay Market include F. Hoffmann-La Roche Ltd. (Switzerland), Siemens AG (Germany), Abbott Laboratories, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), Ortho-Clinical Diagnostics, Inc. (U.S.), and bioMérieux SA (France). Allergy Diagnostics Market by Product (Assay Kits, Instruments (Immunoassay Analyzer, Luminometer), Consumables, Services), Allergen (Food, Inhaled, Drug), Tests (In Vivo, In Vitro), End User (Hospital, Diagnostic Laboratory) - Forecast to 2021 In Vitro Diagnostics (IVD) Quality Controls Market by Application (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Microbiology) Source (Serum, Blood, Plasma Based Controls) Type (Instrument Specific & Third Party Controls) - Forecast to 2020 MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers. We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. Contact: Mr. Rohan MarketsandMarkets 701 Pike Street Suite 2175, Seattle, WA 98101, United States 1-888-600-6441 Email: sales@marketsandmarkets.com Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/biotechnology Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets

News Article | November 23, 2016
Site: www.newsmaker.com.au

According to Stratistics MRC, the Global Tuberculosis Diagnostics market is accounted for $2.12 billion in 2015 and is expected to reach $3.12 billion by 2022 growing at a CAGR of 5.6% from 2015 to 2022.  Increasing cases of tuberculosis is one of the major factors responsible for high market growth. Furthermore, rising government initiatives, growing requirement of POC in healthcare and increasing geriatric population are some factors that are positively affecting the market. However, lack of awareness among the patients is hindering the market. Detection of Drug Resistance segment is anticipated to grow at a steady growth rate and exploitation of antibiotics contribute to the high prevalence of drug resistance. Asia Pacific is expected to witness a lucrative growth over the forecast period attributed to rapid proliferation of this disease across the region. Some of the key players in this market include Hologic Corporation, Cepheid Inc., Siemens AG, Becton, Dickinson and Company, Abbott Laboratories, Hain Lifesciences GmBH, BioMérieux SA, F.Hoffmann-La Roche AG., Alere, Inc., Sanofi, QIAGEN and Thermo Fisher Scientific, Inc. Test Types Covered: • Detection of Drug Resistance • Detection of Latent Infection • Nucleic Acid Testing • Radiographic Methods • Cytokine Detection Assay • Phage Assay • Diagnostic Laboratory Methods • Other Methods Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK  o Spain  o Rest of Europe      • Asia Pacific o Japan        o China        o India        o Australia        o New Zealand       o Rest of Asia Pacific    • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements

Sarasota, FL, Nov. 30, 2016 (GLOBE NEWSWIRE) -- Zion Research has published a new report titled “Hba1c Testing Device Market by Device Type (Handheld Device and Bench-top Device) and by Technology Type (Ion-exchange HPLC, Enzymatic Assay, Affinity Binding Chromatography, Turbidimetric Inhibition Immunoassay and Other) for Hospitals, Homecare, Diagnostic Laboratory and Research Institutions - Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021”. According to the report, the global HbA1c testing device market accounted for around USD 1.20 billion in 2015 and is expected to reach approximately USD 2.20 billion by 2021, growing at a CAGR of around 11 % between 2016 and 2021. Hemoglobin is the red protein molecule responsible for carrying oxygen from lung to the body’s organ and tissues. Glucose molecule sticks to the N-terminal amino acid of the hemoglobin molecule by nonenzymatic attachment to form a hemoglobin A1c or HbA1c, also called as glycosylated hemoglobin molecule.  Diabetes mellitus is a common form of diabetes, caused by pancreatic insulin deficiency, which affects metabolization of starch and sugar.  HbA1c level reflects the average glucose concentration over the previous period and provides a much better indication of body glucose control than urinary and blood glucose determinations. Browse through 18 Market Tables and 24 Figures spread over 110 Pages and in-depth TOC on “Global Hba1c Testing Device Market: By Type, Technology, Devices, Size, Growth, Trends, Industry Segment and Forecast 2015-2021”. The growth of HbA1c testing device market is propelled by increasing number of diabetes population. Geriatric and obese populations are more prone to diabetes mellitus. Globally, USD 673 billion healthcare expenditure is spent on diabetes management which is 12% of total healthcare expenditure. In 2015, around 5.0 million deaths are due to diabetes.  Moreover, emerging technologies for diabetes management and increasing awareness of diabetes preventive care are projected to fuel the growth of HbA1c testing device market. In addition, increasing doctor’s prescription pattern for HbA1c testing is a key factor for generating more demand for the HbA1c testing device. On another hand, the high cost of device and limitation of results of the certain population like pregnant, elderly and non-Hispanic black could be a roadblock in the market. Nonetheless, untapped market and increasing demand for medical tourism in emerging markets are likely to open new opportunities in the forecast period. Based on the device type, the market of the HbA1c testing device has been classified into the handheld device and bench-top device. Bench-top HbA1c testing device is widely used in the diagnostic laboratory due to minimal handling and fastest & accurate results. Bench-top HbA1c testing device segment has acquired the largest market share of more than 65% in 2015 compared to the handheld device and in forecast period handheld HbA1c testing device is projected to grow at the healthy rate. Browse the full "Hba1c Testing Device Market by Device Type (Handheld Device and Bench-top Device) and by Technology Type (Ion-exchange HPLC, Enzymatic Assay, Affinity Binding Chromatography, Turbidimetric Inhibition Immunoassay and Other) for Hospitals, Homecare, Diagnostic laboratory and Research Institutions - Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021" report at https://www.zionmarketresearch.com/report/hba1c-testing-device-market Based on the technology the market of the HbA1c testing device has been segmented as ion-exchange HPLC, enzymatic assay, affinity binding chromatography, turbidimetric inhibition immunoassay and other. With more than 30% revenue contribution, affinity binding chromatography segment was leading the HbA1c testing device market in 2015 due to increasing investment by the manufacturer in the medical device. HbA1c testing device market is segmented on the basis of end user into hospitals, home care, diagnostic laboratory and research institution. Diagnostic laboratory segment dominated the market followed by home care segment and it is expected to grow at the highest rate in the forecast period. With increasing home care service and demand for homecare HbA1c testing device, homecare segment will exhibit significant growth in the forecast period. Around 44 million people are diabetic and diabetes is one of the leading causes of deaths in North America. This indicates that the demand for the HbA1c testing device is very high and it results in rising healthcare expenditure on diabetes, thus North America was a leading segment in HbA1c testing device market in 2015.  North America HbA1c testing device market is expected to show noticeable growth with emerging technologies in the forecast period. Inquire more about this report @ https://www.zionmarketresearch.com/inquiry/hba1c-testing-device-market In Europe, more than 59 million people are diabetic and it is continuously increasing resulting in increased disability and enormous healthcare expenditure thus in forecast period, Europe HbA1c testing device market is expected to show significant growth. Asia-Pacific is at the peak of the epidemic of diabetes and this is due to rapid urbanization & industrialization and changes in lifestyle factors.  More than 60% of the people with diabetes live in Asia pacific. The effect of chronic diseases in adult life and the resulting epigenetic changes are also responsible for increased risk of diabetes mellitus. China is expected to show the fastest expansion over the forecast period. This will be propelled by an increase in the diabetic population due to urbanization and by expected technology launches. Latin America and the Middle East & Africa HbA1c testing device market is also expected to generate new opportunities in the forecast period. Brazil HbA1c testing device market dominated the Latin America and it is predicted to grow at the noticeable rate in the forecast period. Key operating players in HbA1c testing device market are like Transasia Biomedicals ltd., Abbott Laboratories, Alere, Inc., Arkray, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthcare and Trinity Biotech plc. The report segment of global Hba1c Testing Device Market as follows: Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Abdel-Hamid N.M.,Minia University | Abdel-Hamid N.M.,Diagnostic Laboratory | Abdel-Ghany M.I.,Minia University | Nazmy M.H.,Minia University | Amgad S.W.,Minia University
Environmental Health and Preventive Medicine | Year: 2013

Background and aim: To investigate the possible modulating role of "Nigella sativa" (NS), a plant commonly used in Egyptian traditional medicine, on premalignant perturbations in three glycol-regulatory enzymes in an experimental rat model of hepatocellular carcinoma (HCC). Methods: Thirty-six (36) male albino rats were divided into four groups (n = 9). Group 1 served as a normal control, group 2 was treated with methanolic extract of Nigella sativa (MENS) (1 g/kg/day, orally) for 14 weeks, group 3 received a single intraperitoneal dose of diethyl nitrosamine (DENA) (200 mg/kg), followed 2 weeks later by a subcutaneous injection of carbon tetrachloride (CCl4, 3 ml/kg/week/6 weeks) and group IV was treated with MENS for 2 weeks prior to administration of the carcinogenic combination (DENA + CCl4, as in group 3) until the end of the experiment. The total period of the experiment was 14 weeks. Results: In the DENA + CCl4-treated group, there was a significant increase in the relative liver weight, serum alpha fetoprotein level and the activities of hexokinase, glyceraldehyde phosphate dehydrogenase and glucose 6 phosphate dehydrogenase in both the serum and liver homogenate; this was accompanied by a subsequent decrease in body weight. Pre-treatment with MENS significantly maintained these parameters close to the normal condition. Conclusion: Based on these results, we conclude that MENS has a chemo-preventive effect against the progression into liver malignancy through its modulation of the energy metabolic pathways (i.e. glycolysis) that may be involved in hepatocarcinogenesis. © 2012 The Japanese Society for Hygiene.

Abdel-Hamid N.M.,Minia University | Abdel-Hamid N.M.,Diagnostic Laboratory | Morsy M.A.,Minia University
Journal of Membrane Biology | Year: 2010

Five fluorouracil (5-FU) is extensively used in the treatment of hepatocellular carcinoma (HCC). It is well documented that 5-FU and its metabolites inhibit DNA synthesis through inhibition of thymidylate synthetase. Little is known about additional pathways for 5-FU in managing HCC. The present experiment was mainly designed to study possible biochemical pathways that can be added to 5-FU's mechanisms of action. Four groups of rats constituted a control group (given saline only), a trichloroacetic acid group (TCA, 0.5 g/kg/day for 5 days, orally), a 5-FU-positive group (75 mg/kg body weight, intraperitoneally, once weekly for 3 weeks) and a TCA-treated with 5-FU group (24 h from last TCA dose). We executed both biochemical-serum alpha-fetoprotein (AFP), liver tissue contents of total glycosaminoglycan (TGAGs), collagen (represented as hydroxyproline), total sialic acid (TSA), free glucosamine (FGA) and proteolytic enzyme activity (as pepsin and free cathepsin-D-and histological examinations of the liver tissue. The results revealed histological changes such as central vein congestion and irregularly shaped, substantially enlarged, vesiculated and binucleated hepatocytes. The nuclei were mostly polymorphic and hyperchromatic, and several vacuolation was noticed in the cytoplasm encircling the nucleus with masses of acidophilic material. 5-FU greatly corrected these changes, except that some necrotic and cytotoxic effects of 5-FU were still shown. AFP was significantly elevated in TCA-intoxicated, but reversed in 5-FU-treated, groups. Increased proteolytic activity by TCA was reversed by 5-FU, which also restored TGAG contents to normal; but both TCA and 5-FU depleted collagen content. TCA significantly elevated FGA but depressed TSA; this action was reversed by 5-FU treatment. In conclusion, it is possible that proteolytic activity, expressed as upregulated pepsin and free cathepsin-D activities, is increased in HCC. This is accompanied by extracellular matrix macromolecular disturbance, manifested as decreased TGAGs, collagen and TSA, with marked increase in FGA liver tissue content. The elevated FGA with depressed TSA content of liver tissue may be attributed to a cancer-hampered N-acetylation of FGA into SA. 5-FU administration markedly depressed hepatic tissue proteolysis, possibly reactivated N-acetylation of FGA into SA and elevated TGAGs without stopping tissue fibrosis as collagen was not affected. This study explores additional pathways for the mechanism of action of 5-FU, through conservation of extracellular matrix composition in situ, inhibiting invasion and metastasis in addition to its DNA-disturbing pathway. © 2010 Springer Science+Business Media, LLC.

News Article | December 28, 2016
Site: www.techtimes.com

Wildlife officials in Pennsylvania have identified a common yet highly poisonous shrub as the one that killed a family of bears in a church parking lot earlier this month. Officers from the West Wyoming Police Department received reports of a dead bear cub found at a local parking lot on Dec. 6. When they arrived at the scene, they found four dead bears instead of just one, all of which showed no apparent signs of trauma. The police department said that it considered the death of the bears as suspicious at the time. To find out what could have killed the animals, wildlife officials sent two of the dead bears to the Animal Diagnostic Laboratory at Pennsylvania State University for testing. Following the laboratory tests, officials discovered that the animals were killed not by human interference but by ingesting a poisonous shrub known as an English Yew. The four bears — a bear sow and her three cubs — could have eaten leaves and seeds of the plant, which is known to be very poisonous to humans and animals alike. According to the Pennsylvania Game Commission (PGC), the English Yew (Taxus baccata) is a species of conifer native to Africa, Europe, and southwest Asia. While the plant can grow up to 30 feet in height, it is often pruned into various sizes and configurations. In eastern North America, the English Yew can be found in urban environments, mostly used as an ornamental shrub in gardens. The plant's relatively long life and ability to grow on different soil types make it an ideal choice for topiaries or hedges. The PGC, however, warned that all species of the plant have an alkaloid compound known as taxine, which has been proven to be fatal if ingested. Animals that have single-chambered stomachs are particularly susceptible to the toxin's effects. The game commission believes that the bear sow and her cubs may have been attracted to the yew just when the plant reached its highest toxin levels and no other food sources were available to them at the time. Mark Ternent, a bear biologist for the PGC, explained that black bears often feed the most when they are about to go into hibernation to build their body fat. This would allow them to last all through the winter. It is likely that the bear sow and her cubs were about to enter hibernation, which is why they went out to forage for food. While wildlife officials have encountered bears that have died from unusual causes before, the PGC said this could be the first involving the poisonous shrub. "This unfortunate occurrence was extremely rare and one we hope will not be repeated," Ternent said. © 2017 Tech Times, All rights reserved. Do not reproduce without permission.

Gupta B.K.,P.A. College | Sharma K.,P.A. College | Nayak K.C.,P.A. College | Agrawal T.D.,P.A. College | And 3 more authors.
Transactions of the Royal Society of Tropical Medicine and Hygiene | Year: 2010

Malaria is a rare cause of splenic infarction. Only a few cases have been reported worldwide, mostly associated with Plasmodium falciparum infection. Here we report a series of four acute malaria patients with splenic infarction, two with P. vivax infection, one with P. falciparum and one with a mixed infection (P. vivax and P. falciparum). This small case series suggests that if a patient with malaria is complaining of left upper quadrant abdominal pain, pleuritic left lower chest pain and/or enlarging tender splenomegaly during treatment, splenic infarct should be suspected and managed accordingly to avoid further life-threatening complications. © 2009 Royal Society of Tropical Medicine and Hygiene.

PubMed | University of Veterinary And Pharmaceutical Sciences Brno, Laboratory for Veterinary Molecular Diagnostics, Diagnostic Laboratory and Academy of Sciences of the Czech Republic
Type: | Journal: Journal of feline medicine and surgery | Year: 2016

Dermatophytosis, commonly known as ringworm, is a superficial fungal skin disease and zoonosis. Pythium oligandrum is a micromycete with mycoparasitic properties that is used in agriculture to control fungal infections on plants. Formulations containing P oligandrum were also developed for the treatment of dermatophytoses, but only several case studies have been published. In order to document the process in simplified conditions in vitro, we investigated the effectiveness of P oligandrum against three pathogenic dermatophytes common in domestic animals.Cultures of the pathogens grown on nutrient media and experimentally infected cat hair were treated with P oligandrum preparations in therapeutic concentration and the changes were documented by microscopic videos and scanning electron microscopy.There was strong mycoparasitic activity of P oligandrum against Microsporum canis, Microsporum gypseum and Trichophyton mentagrophytes.P oligandrum was demonstrated to be effective against three common causes of dermatophytosis in vitro.

News Article | December 22, 2016
Site: www.businesswire.com

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Medical and Diagnostic Laboratory Services Global Market Report 2017" report to their offering. The medical and diagnostic laboratory services market comprises establishments primarily engaged in the detection and prevention of disease. Medical and diagnostic laboratories perform tests on clinical specimens in order to gain insights and information on patients' health conditions. Where is the largest and fastest growing market for medical and diagnostic laboratory services? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The medical and diagnostic laboratory services global market report answers all these questions and many more. The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider healthcare services market, and compares it with other markets. For more information about this report visit http://www.researchandmarkets.com/research/2qh9g2/medical_and

Loading Diagnostic Laboratory collaborators
Loading Diagnostic Laboratory collaborators